Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
Therapeutic Drug Monitoring
|
November 23, 2013
Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models"
Nicholas H G Holford, Thierry Buclin
Therapeutic Drug Monitoring
|
September 11, 2012
Safe and effective variability-a criterion for dose individualization
Nicholas H G Holford, Thierry Buclin
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 3, 2002
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
Robert A Hauser, Nicholas H G Holford
Clinical Pharmacology and Therapeutics
|
April 17, 2002
Determination of maximum effect
Lewis B Sheiner, Nicholas H G Holford
European Journal of Clinical Pharmacology
|
May 19, 2004
No urine, no urinary clearance
Brian J Anderson, Nicholas H G Holford
Pharmaceutical Statistics
|
November 26, 2008
Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis
Berend Arnold Ploeger, Nicholas H G Holford
British Journal of Clinical Pharmacology
|
September 11, 2008
Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure
Satofumi Iida, Haruki Kinoshita, Nicholas H G Holford
British Journal of Clinical Pharmacology
|
July 9, 2002
Clinical pharmacology: principles and practice of drug therapy in medical education
Brian Whiting, Nicholas H G Holford, Evan J Begg
European Journal of Pediatrics
|
June 30, 2006
Population clinical pharmacology of children: general principles
Brian J Anderson, Karel Allegaert, Nicholas H G Holford
European Journal of Pediatrics
|
June 30, 2006
Population clinical pharmacology of children: modelling covariate effects
Brian J Anderson, Karel Allegaert, Nicholas H G Holford
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
Therapeutic Drug Monitoring
|
November 23, 2013
Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models"
Nicholas H G Holford, Thierry Buclin
Therapeutic Drug Monitoring
|
September 11, 2012
Safe and effective variability-a criterion for dose individualization
Nicholas H G Holford, Thierry Buclin
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 3, 2002
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease
Robert A Hauser, Nicholas H G Holford
Clinical Pharmacology and Therapeutics
|
April 17, 2002
Determination of maximum effect
Lewis B Sheiner, Nicholas H G Holford
European Journal of Clinical Pharmacology
|
May 19, 2004
No urine, no urinary clearance
Brian J Anderson, Nicholas H G Holford
Pharmaceutical Statistics
|
November 26, 2008
Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis
Berend Arnold Ploeger, Nicholas H G Holford
British Journal of Clinical Pharmacology
|
September 11, 2008
Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure
Satofumi Iida, Haruki Kinoshita, Nicholas H G Holford
British Journal of Clinical Pharmacology
|
July 9, 2002
Clinical pharmacology: principles and practice of drug therapy in medical education
Brian Whiting, Nicholas H G Holford, Evan J Begg
European Journal of Pediatrics
|
June 30, 2006
Population clinical pharmacology of children: general principles
Brian J Anderson, Karel Allegaert, Nicholas H G Holford
European Journal of Pediatrics
|
June 30, 2006
Population clinical pharmacology of children: modelling covariate effects
Brian J Anderson, Karel Allegaert, Nicholas H G Holford
Page
of 5